Difference between revisions of "Team:IISc Bangalore/Parts"

Line 14: Line 14:
 
<head>
 
<head>
 
<title>Team IISc iGem</title>
 
<title>Team IISc iGem</title>
 +
 +
<meta name="viewport" content="width=device-width, initial-scale=1">
 +
  <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap.min.css">
 +
  <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.12.4/jquery.min.js"></script>
 +
  <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>
 +
 
<link href="css/bootstrap.css" rel="stylesheet" type="text/css" media="all">
 
<link href="css/bootstrap.css" rel="stylesheet" type="text/css" media="all">
 
<script src="https://use.fontawesome.com/fce310c82d.js"></script>
 
<script src="https://use.fontawesome.com/fce310c82d.js"></script>
Line 54: Line 60:
 
         <div class="collapse navbar-collapse" id="myNavbar">
 
         <div class="collapse navbar-collapse" id="myNavbar">
 
         <ul class="nav navbar-nav">
 
         <ul class="nav navbar-nav">
           <li class=" hvr-underline-from-left"><a href="#">Home</a></li>
+
           <li class="hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore">Home</a></li>
           <li class="hvr-underline-from-left"><a href="#">Team</a></li>
+
           <li class="active hvr-underline-from-left"><a href="https://2016.igem.org/Team:IISc_Bangalore/Team">Team</a></li>
<li class="hvr-underline-from-left"><a href="#">Project</a></li>
+
<li class="active hvr-underline-from-left"><a href="#">Parts</a></li>
+
 
        <li class="hvr-underline-from-left"><a href="#">Safety</a></li>
+
<li class="dropdown"><a class="dropdown-toggle" data-toggle="dropdown" href="#">Project </a>
        <li class="hvr-underline-from-left"><a href="#">Attributions</a></li>
+
        <ul class="dropdown-menu">
        <li class="hvr-underline-from-left"><a href="#">Practices</a></li>
+
          <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Description">Description</a></li>
        <li class="hvr-underline-from-left"><a href="#">Awards</a></li>
+
          <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Proof">Proof</a></li>
 +
          <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Demonstrate">Demonstrate</a></li>
 +
          <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Design">Design</a></li>
 +
          <li><a href="https://2016.igem.org/Team:IISc_Bangalore/Experiments">Experiment</a></li>
 
         </ul>
 
         </ul>
  

Revision as of 11:50, 15 October 2016


Team IISc iGem

Basic

Basic ...

Composite

Composite ...

Parts collection

Parts collection...

End note

End note
×

Overview

With the advent of rDNA technology in the late 1970s, medicine, agriculture and several other areas underwent a quantum leap and from that point, progress only hastened, from one only one recombinant pharmaceutical approved for human use (insulin) in 1982 to one hundred and fifty-one FDA approved protein based recombinant pharmaceuticals by 2009[1]. Despite being in high demand (due to the fact that most recombinant products produced on an industrial scale are therapies for chronic diseases like cancer and diabetes), recombinant products are expensive due to several factors like long and expensive development time, high failure rate (~80%) of the products developed, manufacturing costs requiring expensive technologies and processes (bioreactors, column chromatography, sterile conditions, etc) and the involvement of skilled labor on both the manufacturing and the healthcare provider’s side[2]. Treatments with these pharmaceuticals can cost from around 10,000 to 100,000 € per year for a single patient[2]. As scientists and engineers, it seems obvious that our contribution can be most easily and effectively be made at the level of manufacturing costs; to try to bring down the cost of these life-saving products.
Read more

×

Basic

basic
Read more

×

Composite

Composite
Read more

×

Collection

Collection
Read more